20-deoxy-20-[N-benzyl-N-[-1-(3-quinolyl)-1H-1,2,3-triazol-4-yllmethylamino)-5-O-mycaminosyltylonolide

ID: ALA5199514

Chembl Id: CHEMBL5199514

PubChem CID: 86291412

Max Phase: Preclinical

Molecular Formula: C50H68N6O9

Molecular Weight: 897.13

Names and Identifiers

Canonical SMILES:  CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN(Cc2ccccc2)Cc2cn(-c3cnc4ccccc4c3)nn2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CO

Standard InChI:  InChI=1S/C50H68N6O9/c1-8-44-38(30-57)22-31(2)18-19-42(58)32(3)23-37(49(33(4)43(59)25-45(60)64-44)65-50-48(62)46(54(6)7)47(61)34(5)63-50)20-21-55(27-35-14-10-9-11-15-35)28-39-29-56(53-52-39)40-24-36-16-12-13-17-41(36)51-26-40/h9-19,22,24,26,29,32-34,37-38,43-44,46-50,57,59,61-62H,8,20-21,23,25,27-28,30H2,1-7H3/b19-18+,31-22+/t32-,33+,34-,37+,38-,43-,44-,46+,47-,48-,49-,50+/m1/s1

Standard InChI Key:  RWDHCYPAYDLNSW-FKRYAQFOSA-N

Alternative Forms

1. Parent:

   

   ALA5199514

   (4R,5S,6S,7R,9R,11E,13E,15R,16R)-7-[2-[benzyl-[(1-quinolin-3-yltriazol-4-yl)methyl]amino]ethyl]-6-[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-(hydroxymethyl)-5,9,13-trimethyl-1-oxacyclohexadeca-11,13-diene

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 897.13

Molecular Weight (Monoisotopic): 896.5048

AlogP: 5.03

#Rotatable Bonds: 13

Polar Surface Area: 192.83

Molecular Species: NEUTRAL

HBA: 15

HBD: 4

#RO5 Violations: 3

HBA (Lipinski): 15

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 3

CX Acidic pKa: 12.67

CX Basic pKa: 7.94

CX LogP: 5.44

CX LogD: 4.76

Aromatic Rings: 4

Heavy Atoms: 65

QED Weighted: 0.13

Np Likeness Score: 0.50

References

1. Zhai H, Luo C, Yang P, Zhang S, Wang H, Cao Y, Yang Y, Liu H, Kong X, Arhema Frejat FO, Ren C, Shi X, Wu C..  (2022)  Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.,  238  [PMID:35675753] [10.1016/j.ejmech.2022.114495]

Source

Source(1):

• Scientific Literature